Literature DB >> 22980586

Knowledge of the patients regarding leprosy and adherence to treatment.

Karlisson Bezerra Lira1, João Jaime Giffoni Leite, Débora Castelo Branco de Souza Collares Maia, Rafael de Mesquita Ferreira Freitas, Alexsandra Rodrigues Feijão.   

Abstract

Leprosy is a chronic infectious disease caused by Mycobacterium leprae. It is known for its great disfiguring capacity and is considered an extremely serious disease to public health worldwide. The state of Ceará ranks 13th in number of cases of leprosy in Brazil, and fourth in Northeastern region, with an average of 2,149 new cases diagnosed every year. This study aimed to evaluate the knowledge of leprosy patients regarding treatment, and to assess the level of treatment adherence and its possible barriers. The study was conducted in the reference center for dermatology, from September 2010 to October 2010, in Fortaleza, Ceará. The study data were collected by means of a structured interview, along with the Morisky-Green test, in order to assess treatment adherence and barriers to adherence. A total of 70 patients were interviewed, out of whom 66 were new cases. The majority of patients were between 42 and 50 years old, and 37 (52.9%) were male. Most patients were clinically classified as presenting multibacillary leprosy (80%), and 78.6% of them were from Fortaleza, Brazil. The Morisky-Green test indicated that 62.9% of patients presented a low level of adherence (p<0.005), despite claiming to aware of the disease risks. However, it was observed that 57.1% of the patients had no difficulty adhering to treatment, while 38.6% reported little difficulty. This study shows that despite the patients claiming to be familiar with leprosy and its treatment, the Morisky-Green test clearly demonstrated that they actually were not aware of the principles of therapy, which is evidenced by the low degree of treatment adherence.
Copyright © 2012 Elsevier Editora Ltda. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22980586     DOI: 10.1016/j.bjid.2012.04.002

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  5 in total

1.  Leprosy treatment dropout: a systematic review.

Authors:  Régio José Santiago Girão; Nara Lívia Rezende Soares; Juliana Viana Pinheiro; Giuliano da Paz Oliveira; Sionara Melo Figueiredo de Carvalho; Luiz Carlos de Abreu; Vitor E Valenti; Fernando Luiz Affonso Fonseca
Journal:  Int Arch Med       Date:  2013-08-30

2.  WHO multidrug therapy for leprosy: epidemiology of default in treatment in Agra district, Uttar Pradesh, India.

Authors:  Anil Kumar; Anita Girdhar; Joy Kumar Chakma; Bhuwneswar Kumar Girdhar
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

3.  The Stress of Leprosy as a Mediator of the Relationship Between Coping Resources, Coping Strategies, and Psychological Well-Being in Persons Affected by Leprosy. The Structural Equation Models Through a Correlation Study.

Authors:  Muhammad Yulianto Listiawan; Cita Rosita Sigit Prakoeswa; Medhi Denisa Alinda; Bagus Haryo Kusumaputra; Felix Hartanto; Abd Nasir; Ah Yusuf
Journal:  J Multidiscip Healthc       Date:  2022-09-29

4.  Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.

Authors:  Madelon Novato Ribeiro; Maria Inês Fernandes Pimentel; Armando de Oliveira Schubach; Raquel de Vasconcellos Carvalhães de Oliveira; José Liporage Teixeira; Madson Pedro da Silva Leite; Monique Fonseca; Ginelza Peres Lima dos Santos; Mariza Matos Salgueiro; Erica de Camargo Ferreira e Vasconcellos; Marcelo Rosandiski Lyra; Mauricio Naoto Saheki; Claudia Maria Valete-Rosalino
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jul-Aug       Impact factor: 1.846

5.  Key sources of strength and resilience for persons receiving services for Hansen's disease (leprosy) in Porto Velho, Brazil: What can we learn for service development?

Authors:  Anna T Van't Noordende; Zoica Bakirtzief da Silva Pereira; Pim Kuipers
Journal:  Int Health       Date:  2021-12-01       Impact factor: 2.473

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.